BioSyent : FeraMAX Named 1 Recommended Iron Supplement by National Pharmacists and Physicians for Fifth Consecutive Year
May 04, 2020 at 08:39 am EDT
Share
BioSyent Inc. ('BioSyent', TSX Venture: RX) is pleased to announce that for the fifth consecutive year, FeraMAX has been named the #1 recommended iron supplement brand in a national survey of Canadian pharmacists and physicians.
The 2020 Survey on OTC Counselling & Recommendations was conducted by Ensemble IQ, Research, Insights and Innovation team and the following publications and websites: Pharmacy Practice + Business, The Medical Post, Profession Sante, CanadianHealthcareNetwork.ca and ProfessionSante.ca. This annual online survey was conducted between October 2019 and January 2020 with Canadian retail pharmacists and physicians. In total, 1,426 surveys were completed by Canadian pharmacists and 654 surveys were completed by Canadian physicians. FeraMAX was named as the most recommended iron supplement brand nationally both by pharmacists and physicians. The percentage of recommendations was 48% among national pharmacists and 47% among national physicians. This is a significant achievement, considering the competitive iron supplement landscape. 'We are very proud that FeraMAX has maintained its #1 ranking among Canadian healthcare professionals for a fifth consecutive year,' commented Mr. Rene Goehrum, President and CEO of BioSyent. 'We are grateful for the ongoing support of these healthcare professionals in continuing to recommend FeraMAX to their patients. We look forward to continuing to build on the success of FeraMAX in Canada.'
About FeraMAX
FeraMAX 150 is an oral iron supplement indicated for the prevention and treatment of iron deficiency anaemia. This non-ionic polysaccharide-iron complex formulation offers several benefits compared to conventional iron salt supplements and is welltolerated. FeraMAX is Vegan Certified and provides an iron therapy option for vegans, vegetarians, and patients with other dietary restrictions. FeraMAX is also recognized by the Society of Obstetricians and Gynaecologists of Canada. FeraMAX Powder, based upon the same innovative non-ionic polysaccharide-iron complex technology found in FeraMAX 150, is available in a pleasant tasting, dissolvable powder for pediatric patients.
About BioSyent Inc.
Listed on the TSX Venture Exchange under the trading symbol 'RX', BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, hospital and international business units.
BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary operates the Companyâs business marketing biologically and health friendly non-chemical insecticides. Its products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Cathejell combines sterile gel and 2% lidocaine jelly in a collapsible syringe that is ready to use. FeraMAX Pd Therapeutic 150 is an oral hematinic that helps the body form red blood cells and is indicated for the treatment of iron deficiency anemia.
BIOSYENT INC. 
